Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 22,631 Shares of Stock

Edwards Lifesciences Corp (NYSE:EW) VP Patrick B. Verguet sold 22,631 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $113.16, for a total transaction of $2,560,923.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Patrick B. Verguet also recently made the following trade(s):

  • On Monday, May 15th, Patrick B. Verguet sold 11,500 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $111.64, for a total transaction of $1,283,860.00.
  • On Thursday, March 30th, Patrick B. Verguet sold 24,000 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $93.90, for a total transaction of $2,253,600.00.

Edwards Lifesciences Corp (NYSE:EW) traded up 0.84% during mid-day trading on Friday, hitting $112.89. 1,079,374 shares of the stock were exchanged. The company has a 50 day moving average price of $102.70 and a 200 day moving average price of $94.65. Edwards Lifesciences Corp has a 52-week low of $81.12 and a 52-week high of $121.75. The firm has a market cap of $23.68 billion, a price-to-earnings ratio of 37.53 and a beta of 0.53.

Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.12. The company had revenue of $883.50 million for the quarter, compared to the consensus estimate of $776.51 million. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The company’s revenue for the quarter was up 26.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.71 EPS. On average, analysts anticipate that Edwards Lifesciences Corp will post $3.53 EPS for the current year.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corp (NYSE:EW)

TRADEMARK VIOLATION NOTICE: “Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 22,631 Shares of Stock” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/19/insider-selling-edwards-lifesciences-corp-ew-vp-sells-22631-shares-of-stock.html.

A number of equities research analysts recently commented on the stock. Cowen and Company reissued an “outperform” rating and set a $120.00 target price on shares of Edwards Lifesciences Corp in a research report on Tuesday, March 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corp from a “hold” rating to a “buy” rating and set a $127.00 target price for the company in a research report on Tuesday. Northland Securities reissued a “positive” rating and set a $105.00 target price on shares of Edwards Lifesciences Corp in a research report on Thursday, February 2nd. Leerink Swann cut shares of Edwards Lifesciences Corp from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 2nd. Finally, Credit Suisse Group AG set a $120.00 target price on shares of Edwards Lifesciences Corp and gave the company a “buy” rating in a research report on Wednesday, February 8th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $119.77.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Quadrant Capital Group LLC increased its position in shares of Edwards Lifesciences Corp by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares in the last quarter. YorkBridge Wealth Partners LLC acquired a new position in shares of Edwards Lifesciences Corp during the first quarter valued at approximately $110,000. NEXT Financial Group Inc increased its position in shares of Edwards Lifesciences Corp by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares in the last quarter. TCI Wealth Advisors Inc. increased its position in shares of Edwards Lifesciences Corp by 30.5% in the third quarter. TCI Wealth Advisors Inc. now owns 1,044 shares of the medical research company’s stock valued at $126,000 after buying an additional 244 shares in the last quarter. Finally, Advantage Investment Management LLC acquired a new position in shares of Edwards Lifesciences Corp during the fourth quarter valued at approximately $145,000. 83.99% of the stock is currently owned by institutional investors.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

5 Day Chart for NYSE:EW

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply